ClassID:

97296

C07K2317/73 - page 12 - CPC Classification

Classification description:

Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Recent Application in this class:
#3301
20160046713
2016-02-18

Anti-KIR3D antibodies

#3302
20160046712
2016-02-18

KIR-binding agents and methods of use thereof

#3303
20160046711
2016-02-18

Anti-CDH6 antibody drug conjugates

#3304
20160046706
2016-02-18

Antibody against human NRG1 protein

#3305
20160039948
2016-02-11

Antibody constructs for influenza M2 and CD3

#3306
20160039934
2016-02-11

CD3 binding domains

#3307
20160039929
2016-02-11

Methods for treating IL-6 mediated diseases with antibody molecules specific for IL-6

#3308
20160039921
2016-02-11

Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence

#3309
20160038578
2016-02-11

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof

#3310
20160032019
2016-02-04

Antibody constructs for CDH19 and CD3

#3311
20160032017
2016-02-04

Antibodies specific to a novel epitope on CεMX of human membrane-bound IgE and uses thereof in treating IgE-mediated diseases

#3312
20160032011
2016-02-04

HER3 specific monoclonal antibodies for diagnostic and therapeutic use

#3313
20160032006
2016-02-04

THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS

#3314
20160032005
2016-02-04

METHODS AND PHARMACEUTICALS COMPOSITIONS FOR TREATING BREAST CANCERS

#3315
20160032004
2016-02-04

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

#3316
20160032003
2016-02-04

Therapeutic use of anti-CD22 antibodies for inducing trogocytosis

#3317
20160031986
2016-02-04

Therapeutic DLL4 binding proteins

#3318
20160031984
2016-02-04

Humanized antibodies that bind LGR5

#3319
20160031974
2016-02-04

Method of treatment with antibodies having specificity for human OX40

#3320
20160030594
2016-02-04

cKIT antibody drug conjugates

#3321
20160024225
2016-01-28

Proteins specific for BAFF and B7RP1 and uses thereof

#3322
20160024219
2016-01-28

Anti-CD52 antibodies

#3323
20160024215
2016-01-28

LLT-1 antibodies with new functional properties

#3324
20160024211
2016-01-28

Methods of modulating immune function

#3325
20160024194
2016-01-28

Compositions and methods for treating angiogenesis-related disorders

#3326
20160017058
2016-01-21

BISPECIFIC ANTIBODIES AND USES THEREOF

#3327
20160017054
2016-01-21

Spermidine/Spermine N1 - Acetyltransferase Antibodies As Anti-Cancer Drug Compounds

#3328
20160017053
2016-01-21

Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates Thereof

#3329
20160017047
2016-01-21

CD20-binding immunotoxins for inducing cellular internalization and methods using same

#3330
20160017044
2016-01-21

Antibody fragments, compositions and uses thereof

#3331
20160017040
2016-01-21

Anti-B7-H4 antibodies and immunoconjugates

#3332
20160017038
2016-01-21

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

#3333
20160017034
2016-01-21

COMPOSITION FOR TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER

#3334
20160017033
2016-01-21

COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE

#3335
20160017028
2016-01-21

Method for treating a disease originated from receptor activation by EREG and TGFα

#3336
20160015831
2016-01-21

ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF

#3337
20160015829
2016-01-21

Photosensitizing antibody-fluorophore conjugates

#3338
20160015827
2016-01-21

Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof

#3339
20160015809
2016-01-21

M-CSF specific monoclonal antibody and uses therof

#3340
20160015732
2016-01-21

Compositions and methods for inducing apoptosis

#3341
20160009811
2016-01-14

Endoglin antibodies

#3342
20160009768
2016-01-14

Modified toxins

#3343
20160008429
2016-01-14

Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer

#3344
20160002356
2016-01-07

Coiled coil and/or tether containing protein complexes and uses thereof

#3345
20160002344
2016-01-07

Anti-RSPO2 antibodies and uses thereof

#3346
20160002338
2016-01-07

Anti-HER3 antibodies binding to the beta-hairpin of HER3

#3347
20160002335
2016-01-07

Therapeutic use of anti-CS1 antibodies

#3348
20160002334
2016-01-07

Bi-specific antibodies against Tim-3 and PD-1 for immunotherapy in chronic immune conditions

#3349
20160002333
2016-01-07

Bispecific CD33 and CD3 binding proteins

#3350
20160002324
2016-01-07

Caninized anti-NGF antibodies and their use

#3351
20160002322
2016-01-07

Antibodies against TM4SF5 and methods of use thereof

#3352
20160000915
2016-01-07

Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells

#3353
20150376701
2015-12-31

BIOMARKERS OF AUTOIMMUNE AND/OR CHRONIC DISEASES ASSOCIATED WITH JOINT INFLAMMATION

#3354
20150376293
2015-12-31

Methods of producing antibodies specific for p95

#3355
20150376292
2015-12-31

Anti c-Met antibodies

#3356
20150376291
2015-12-31

Anti c-Met antibodies

#3357
20150376279
2015-12-31

Cell penetrating nucleolytic antibody based cancer therapy

#3358
20150376276
2015-12-31

Anti-NTB-A antibodies and related compositions and methods

#3359
20150376274
2015-12-31

Treatment of peripheral T cell lymphoma

#3360
20150376269
2015-12-31

Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense

#3361
20150374789
2015-12-31

Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma

#3362
20150368356
2015-12-24

TUMOR SPECIFIC ANTIBODIES AND USES THEREFOR

#3363
20150368353
2015-12-24

Anti-Podoplanin Antibodies and Methods of Use

#3364
20150368343
2015-12-24

Antibody constructs for CDH19 and CD3

#3365
20150368340
2015-12-24

Human monoclonal antibodies specific for glypican-3 and use thereof

#3366
20150366989
2015-12-24

Anti-TAT226 antibodies and immunoconjugates

#3367
20150366909
2015-12-24

Methods for expansion or depletion of T-regulatory cells

#3368
20150361165
2015-12-17

MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors

#3369
20150359799
2015-12-17

Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders

#3370
20150355177
2015-12-10

Diagnosis of a neurological disease

#3371
20150353645
2015-12-10

Human monoclonal antibodies to ganglioside GD2

#3372
20150353644
2015-12-10

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

#3373
20150353638
2015-12-10

Humanized monoclonal antibodies against the extracellular domain of human death receptor 5

#3374
20150353637
2015-12-10

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

#3375
20150344583
2015-12-03

BCMA antigen binding proteins

#3376
20150344573
2015-12-03

Humanized anti-CD22 antibody

#3377
20150344572
2015-12-03

Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

#3378
20150344559
2015-12-03

Anti-TNF-alpha glycoantibodies and uses thereof

#3379
20150343088
2015-12-03

Antibody recognizing folate receptors α and β

#3380
20150343082
2015-12-03

Methods of making and using chemically self assembled-nanorings

#3381
20150337053
2015-11-26

Antibody Fc mutants with ablated effector functions

#3382
20150337048
2015-11-26

Anti-CD324 monoclonal antibodies and uses thereof

#3383
20150337043
2015-11-26

Anti-EGFR antibodies and uses thereof

#3384
20150337042
2015-11-26

Anti-EGFR antibodies and antibody drug conjugates

#3385
20150329641
2015-11-19

Antibodies which bind to epithelial membrane protein 2 (EMP2)

#3386
20150329637
2015-11-19

DEPLETION OF IL23R EXPRESSING CELLS IN THE TREATMENT OF VARIOUS DISEASES

#3387
20150329628
2015-11-19

Liquid formulations for an anti-TNF α antibody

#3388
20150329627
2015-11-19

Ang2 antibodies

#3389
20150322165
2015-11-12

Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

#3390
20150322162
2015-11-12

Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same

#3391
20150322161
2015-11-12

Recombinant human IgM-antibody effective against cancer cells

#3392
20150322151
2015-11-12

Antibodies targeting CDH19 for melanoma

#3393
20150322145
2015-11-12

Therapeutic use of antibodies to HGF

#3394
20150322138
2015-11-12

MDR specific antibody

#3395
20150320880
2015-11-12

ANTIBODY DRUG CONJUGATES

#3396
20150315293
2015-11-05

Anti-PTK7 antibody-drug conjugates

#3397
20150315290
2015-11-05

Multispecific antibodies

#3398
20150315287
2015-11-05

Antibody to genetic products differentially expressed in tumors and the use thereof

#3399
20150315278
2015-11-05

Anti-Glypican-3 Antibody Having Improved Kinetics in Plasma

#3400
20150315277
2015-11-05

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

#3401
20150315275
2015-11-05

Anti-human B7-H4 antibodies and their uses

#3402
20150315274
2015-11-05

Anti-PD1 antibodies and their use as therapeutics and diagnostics

#3403
20150314016
2015-11-05

Anti-CD79B antibodies and immunoconjugates and methods of use

#3404
20150314007
2015-11-05

LINKER-PAYLOAD MOLECULE CONJUGATES

#3405
20150307629
2015-10-29

Bispecific antibodies that bind to CD38 and CD3

#3406
20150307621
2015-10-29

Anti-CD98 antibody processes

#3407
20150307612
2015-10-29

Biological materials related to c-Met

#3408
20150306245
2015-10-29

Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins

#3409
20150299334
2015-10-22

Stem cell enhancing therapeutics

#3410
20150299330
2015-10-22

Nucleic acid molecules encoding anti-CD27 antibodies

#3411
20150299326
2015-10-22

Fully human antibodies and fragments recognizing human c-Met

#3412
20150299325
2015-10-22

Anti-blood dendritic cell antigen 2 antibodies and uses thereof

#3413
20150299321
2015-10-22

Compositions monovalent for CD28 binding and methods of use

#3414
20150299300
2015-10-22

METHOD OF TREATING CANCER

#3415
20150299265
2015-10-22

Binding proteins comprising at least two repeat domains against HER2

#3416
20150292031
2015-10-15

Treatment of angiogenesis disorders

#3417
20150291698
2015-10-15

Methods and products for preventing and/or treating metastatic cancer

#3418
20150291697
2015-10-15

Antibody capable of specifically recognizing transferrin receptor

#3419
20150291694
2015-10-15

Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody

#3420
20150291693
2015-10-15

Immunoproteases

#3421
20150291691
2015-10-15

Methods for cancer management targeting Co-029

#3422
20150291685
2015-10-15

Antibodies to surface determinants

#3423
20150290317
2015-10-15

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

#3424
20150290308
2015-10-15

Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma

#3425
20150285806
2015-10-08

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

#3426
20150284468
2015-10-08

Method for treatment of blood tumor using anti-TIM-3 antibody

#3427
20150284467
2015-10-08

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

#3428
20150284463
2015-10-08

Bispecific HER2 ligands for cancer therapy

#3429
20150284456
2015-10-08

Antibodies to TGF-β

#3430
20150283178
2015-10-08

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

#3431
20150274840
2015-10-01

Anti-ADAM28 antibody for treating cancer

#3432
20150274839
2015-10-01

Antibodies to non-functional P2X7 receptor

#3433
20150274836
2015-10-01

Mesothelin antibodies and methods for eliciting potent antitumor activity

#3434
20150274835
2015-10-01

Human monoclonal anti-PD-L1 antibodies and methods of use

#3435
20150274833
2015-10-01

Recombinant bispecific antibody binding to CD20 and CD95

#3436
20150274832
2015-10-01

DAC HYP compositions and methods

#3437
20150274831
2015-10-01

Antibodies against human CSF-1R and uses thereof

#3438
20150274830
2015-10-01

Antibodies against human CSF-1R and uses thereof

#3439
20150274829
2015-10-01

Compositions and methods relating to anti-IGF-1 receptor antibodies

#3440
20150274828
2015-10-01

Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof

#3441
20150274827
2015-10-01

Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor

#3442
20150274824
2015-10-01

ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER

#3443
20150274820
2015-10-01

Stable and soluble antibodies inhibiting VEGF

#3444
20150274818
2015-10-01

Compounds and methods for treating pain

#3445
20150266967
2015-09-24

SUPERIOR EFFICACY OF CD37 ANTIBODIES IN CLL BLOOD SAMPLES

#3446
20150266966
2015-09-24

Methods and antibody compositions for tumor treatment

#3447
20150266963
2015-09-24

Antibodies to CD70

#3448
20150266959
2015-09-24

Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis

#3449
20150266954
2015-09-24

IL-21 antibodies and methods of making or using the antibodies

#3450
20150265722
2015-09-24

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

#3451
20150259432
2015-09-17

Method of inhibiting or treating cancer metastasis

#3452
20150259428
2015-09-17

CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same

#3453
20150259409
2015-09-17

Anti-BLyS antibody

#3454
20150252117
2015-09-10

Anti-Jagged1 antibodies and methods of use

#3455
20150252115
2015-09-10

In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody

#3456
20150252113
2015-09-10

ANTI-ErbB2 ANTIBODIES

#3457
20150252104
2015-09-10

Monoclonal antibodies against claudin-18 for treatment of cancer

#3458
20150252103
2015-09-10

Monoclonal antibodies against claudin-18 for treatment of cancer

#3459
20150250152
2015-09-10

TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND VK REGIONS AND ANTIBODIES PRODUCED THEREFROM

#3460
20150246971
2015-09-03

JAM-C antibodies and methods for treatment of cancer

#3461
20150246967
2015-09-03

Human domain antibodies against components of the human insulin-like growth factor (IGF) system

#3462
20150246122
2015-09-03

Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies

#3463
20150239981
2015-08-27

ANTIBODY FC VARIANTS

#3464
20150239978
2015-08-27

Antibodies directed against ICOS for treating graft-versus-host disease

#3465
20150232573
2015-08-20

Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

#3466
20150232570
2015-08-20

Methods of Treating Hematological Malignancies with Notch1 Antibodies

#3467
20150232569
2015-08-20

Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

#3468
20150232557
2015-08-20

CD3 binding polypeptides

#3469
20150225484
2015-08-13

ANTIGEN-BINDING MOLECULE AND USES THEREOF

#3470
20150225469
2015-08-13

Method for regulating cell proliferation

#3471
20150225457
2015-08-13

Modulation of the immune response

#3472
20150218286
2015-08-06

Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin

#3473
20150218283
2015-08-06

Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof

#3474
20150218249
2015-08-06

Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis

#3475
20150216972
2015-08-06

Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor

#3476
20150212077
2015-07-30

Biomarker TFF1 for predicting effect of C-MET inhibitor

#3477
20150203586
2015-07-23

Macromolecular compositions that cross the blood-brain barrier and methods of use thereof

#3478
20150203583
2015-07-23

DAC HYP compositions and methods

#3479
20150203578
2015-07-23

Anti-Siglec-8 antibodies and methods of use thereof

#3480
20150203573
2015-07-23

Monoclonal antibody against human midkine

#3481
20150203555
2015-07-23

α/β-peptide mimics of Z-domain peptides

#3482
20150197573
2015-07-16

DAC HYP compositions and methods

#3483
20150197566
2015-07-16

Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19

#3484
20150197563
2015-07-16

Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3

#3485
20150197562
2015-07-16

Anti-plasmodium parasite antibodies

#3486
20150197561
2015-07-16

Jagged-binding agents and uses thereof

#3487
20150196660
2015-07-16

Anti-ETBR antibodies and immunoconjugates

#3488
20150191546
2015-07-09

Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

#3489
20150191536
2015-07-09

Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

#3490
20150183884
2015-07-02

Alpha-enolase specific antibodies and methods of uses in cancer therapy

#3491
20150183883
2015-07-02

Anti-ETBR antibodies and immunoconjugates

#3492
20150183881
2015-07-02

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

#3493
20150183870
2015-07-02

Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies

#3494
20150175976
2015-06-25

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

#3495
20150175708
2015-06-25

Multifunctional antibodies binding to EGFR and MET

#3496
20150175701
2015-06-25

OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE

#3497
20150175697
2015-06-25

Deimmunized serum-binding domains and their use in extending serum half-life

#3498
20150175693
2015-06-25

IL-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of IL-3

#3499
20150175686
2015-06-25

Monoclonal antibodies for treatment of cancer

#3500
20150166963
2015-06-18

Notch1 receptor binding agents and methods of use thereof

#3501
20150166665
2015-06-18

Cytotoxic immunoglobulin

#3502
20150166664
2015-06-18

NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION

#3503
20150166661
2015-06-18

Anti-CD3 antibodies and methods of use

#3504
20150165075
2015-06-18

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy

#3505
20150158952
2015-06-11

CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

#3506
20150158950
2015-06-11

Antibodies against human CSF-1R and uses thereof

#3507
20150158938
2015-06-11

Gremlin-1 antibody

#3508
20150158933
2015-06-11

HIV antigens and antibodies and compositions, uses and methods thereof

#3509
20150157711
2015-06-11

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

#3510
20150152192
2015-06-04

Anti-C-Met/anti-Ang2 bispecific antibody

#3511
20150152180
2015-06-04

PD-1 specific antibodies and uses thereof

#3512
20150152177
2015-06-04

Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2

#3513
20150147344
2015-05-28

BTLA antibodies and uses thereof

#3514
20150147342
2015-05-28

Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody

#3515
20150147330
2015-05-28

High-affinity monoclonal antibodies to glypican-3 and use thereof

#3516
20150147322
2015-05-28

Compositions and methods for targeting type 1 interferon producing cells

#3517
20150147316
2015-05-28

CD33 antibodies and use of same to treat cancer

#3518
20150147278
2015-05-28

Antibody against transporter and use thereof

#3519
20150140609
2015-05-21

Anti-αβantibodies

#3520
20150140023
2015-05-21

Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers

#3521
20150140019
2015-05-21

Compositions and Methods for Regulating CAR T Cells

#3522
20150140011
2015-05-21

IL-6 binding molecules

#3523
20150139951
2015-05-21

Methods of treating tumors with engineered antibody-interferon mutant fusion molecules

#3524
20150132336
2015-05-14

Immunogenic compositions of antigens

#3525
20150132317
2015-05-14

Methods and compositions for treating neuroblastoma

#3526
20150132307
2015-05-14

Bispecific antibodies against human TWEAK and human IL17 and uses thereof

#3527
20150132292
2015-05-14

Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers

#3528
20150132220
2015-05-14

Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides

#3529
20150132217
2015-05-14

Disease therapy by inducing immune response to Trop-2 expressing cells

#3530
20150126713
2015-05-07

Anti-human IL-23 receptor antibody and encoding polynucleotides

#3531
20150119557
2015-04-30

In vitro culture conditions for T-cell acute lymphoblastic leukemia/lymphoma

#3532
20150118750
2015-04-30

Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof

#3533
20150118234
2015-04-30

Substance specific to human PD-1

#3534
20150118227
2015-04-30

Antibody Fc mutants with ablated effector functions

#3535
20150110793
2015-04-23

Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

#3536
20150110787
2015-04-23

Antibodies or antigen-binding fragments thereof specifically binding to VEGF-C and use thereof

#3537
20150104808
2015-04-16

Cysteine engineered fibronectin type III domain binding molecules

#3538
20150104443
2015-04-16

Anti-ErbB2 antibody variants

#3539
20150099861
2015-04-09

Anti-αβTCR antibody

#3540
20150098949
2015-04-09

VEGF binding antibodies

#3541
20150098947
2015-04-09

Monoclonal Olfml-3 antibodies and uses thereof

#3542
20150098943
2015-04-09

Protein constructs designed for targeting and lysis of cells

#3543
20150093395
2015-04-02

Anti-fXI antibodies and methods of use

#3544
20150093386
2015-04-02

Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen

#3545
20150093380
2015-04-02

Immunopotentiative composition

#3546
20150087810
2015-03-26

Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof

#3547
20150086574
2015-03-26

Antibodies that specifically bind to TIM3

#3548
20150086568
2015-03-26

Anti-VEGF antibodies

#3549
20150086558
2015-03-26

Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains

#3550
20150086478
2015-03-26

Humanized pan-HER antibody compositions

#3551
20150079092
2015-03-19

Methods for binding members of interleukin-4 receptor α (IL-4Rα)

#3552
20150079088
2015-03-19

Multispecific antibodies, multispecific activatable antibodies and methods of using the same

#3553
20150071933
2015-03-12

Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma

#3554
20150071931
2015-03-12

LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same

#3555
20150071930
2015-03-12

Combination therapy using c-Met inhibitor and beta-catenin inhibitor

#3556
20150071929
2015-03-12

Anti-NKG2A antibodies and uses thereof

#3557
20150071927
2015-03-12

Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof

#3558
20150064208
2015-03-05

Polyvalent chimeric OSPC vaccinogen and diagnostic antigen

#3559
20150064203
2015-03-05

ANTICANCER AGENT

#3560
20150064198
2015-03-05

Enhancing immunity to tuberculosis

#3561
20150064190
2015-03-05

Antibodies to tumor endothelial marker 7R

#3562
20150057437
2015-02-26

Anti-CD40 antibody mutants

#3563
20150056270
2015-02-26

Method for producing liposome encapsulating paclitaxel monoglycoside and/or docetaxel monoglycoside

#3564
20150056222
2015-02-26

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

#3565
20150056221
2015-02-26

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

#3566
20150056214
2015-02-26

Monoclonal antibodies that bind B7H6 and uses thereof

#3567
20150056159
2015-02-26

The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity

#3568
20150051266
2015-02-19

Chimeric antigen receptors targeting B-cell maturation antigen

#3569
20150050294
2015-02-19

Methods for diagnosing and treating neuroendocrine cancer

#3570
20150050287
2015-02-19

Anti-CXCL13 antibodies and methods of using the same

#3571
20150050286
2015-02-19

Anti-NGF antibodies and methods using same

#3572
20150050276
2015-02-19

High affinity antibodies that neutralize enterotoxin B

#3573
20150050273
2015-02-19

AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES

#3574
20150050266
2015-02-19

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

#3575
20150047065
2015-02-12

Binding molecules with antitumoral activity

#3576
20150044722
2015-02-12

Nucleic acids encoding anti-Siglec-15 antibodies

#3577
20150044226
2015-02-12

Anti-phospholipase D4 antibody

#3578
20150044219
2015-02-12

Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases

#3579
20150044210
2015-02-12

MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS

#3580
20150044197
2015-02-12

Antibodies that specifically bind to the EphA2 receptor

#3581
20150044164
2015-02-12

Methods of treating autoimmune diseases

#3582
20150044134
2015-02-12

Compositions, methods and kits for treatment of cancer and autoimmune diseases

#3583
20150038682
2015-02-05

ANTIBODIES OR FUSION PROTEINS MULTIMERIZED VIA HOMOMULTIMERIZING PEPTIDE

#3584
20150037886
2015-02-05

TREATMENT DRUG FOR AUTOIMMUNE DISEASES AND ALLERGIC DISEASES

#3585
20150037340
2015-02-05

Antigen binding protein and its use as addressing product for the treatment of cancer

#3586
20150037328
2015-02-05

Anti-CXCR4 antibodies and antibody-drug conjugates

#3587
20150037322
2015-02-05

Methods and compositions for inhibiting CD32B expressing cells

#3588
20150037321
2015-02-05

Methods and compositions for inhibiting CD32b expressing cells

#3589
20150037248
2015-02-05

IL-1β neutralizing human monoclonal antibodies

#3590
20150030605
2015-01-29

POLYPEPTIDES AND POLYNUCLEOTIDES FOR ARTEMIN AND RELATED LIGANDS, AND METHODS OF USE THEREOF

#3591
20150030599
2015-01-29

Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same

#3592
20150030596
2015-01-29

Bispecific chimeric proteins comprising DARPins

#3593
20150024459
2015-01-22

Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors

#3594
20150023967
2015-01-22

Binding molecules for BCMA and CD3

#3595
20150023958
2015-01-22

Fusion polypeptide inhibiting VEGF-C, VEGF-D and/or angiopoietin-2, and use thereof

#3596
20150017230
2015-01-15

Anti-epithelial cell adhesion molecule (EpCAM) antibodies and methods of use thereof

#3597
20150017187
2015-01-15

Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use

#3598
20150017160
2015-01-15

Combinations and uses thereof

#3599
20150017096
2015-01-15

HER3 inhibitor for modulating radiosensitivity

#3600
20150010574
2015-01-08

Anti-IGF antibodies